Bristol-Myers Squibb Company

09/20/2021 | Press release | Distributed by Public on 09/20/2021 05:00

U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as[...]